Last $7.65 USD
Change Today -0.02 / -0.26%
Volume 25.1K
As of 8:10 PM 06/18/13 All times are local (Market data is delayed by at least 15 minutes).

lonza group ag-unspon adr (LZAGY) Snapshot

Open
$7.63
Previous Close
$7.67
Day High
$7.65
Day Low
$7.60
52 Week High
06/10/13 - $7.89
52 Week Low
06/19/12 - $3.64
Market Cap
4.0B
Average Volume 10 Days
53.2K
EPS TTM
--
Shares Outstanding
529.2M
EX-Date
04/11/13
P/E TM
--
Dividend
$0.23
Dividend Yield
3.01%
Current Stock Chart for LONZA GROUP AG-UNSPON ADR (LZAGY)

Related News

No related news articles were found.

lonza group ag-unspon adr (LZAGY) Related Businessweek News

View More BusinessWeek News

lonza group ag-unspon adr (LZAGY) Details

Lonza Group AG supplies products and services to the pharmaceutical and biotechnology, healthcare, and life-science industries worldwide. Its Custom Manufacturing segment manufactures active ingredients that are used in critical drugs for treating patients with cardiovascular diseases, cancer, neurological, and infectious diseases. The company’s Life Science Ingredients segment offers products used in nutrition, microbial control, and selected industrial markets. This segment’s ingredients range from nutritional ingredients that support improved health to complex chemical intermediates for the agricultural industry. It serves manufacturers of consumer and health products, distributors, formulators, and service companies. The company’s Microbial Control segment provides chemistry-based and related solutions to destroy or selectively inhibit the growth of harmful microorganisms in the areas of water treatment, personal care, health and hygiene, industrial preservation, materials protection, and wood treatment. Its product range includes swimming pool and spa treatment chemicals, active biocides for hospital disinfectants, and metalfree wood preservatives, as well as sanitizers and household cleaning products. The company’s Bioscience segment develops tools that help life science customers to discover, develop, and test therapeutics. Its products range from cell culture and molecular biology tools for life-science research to media used in the production of therapeutics and tests for microbial detection. This segment also offers custom manufacturing services to cell therapy companies. It serves pharmaceutical and biotechnology companies, and academic and government research organizations. The company was founded in 1897 and is headquartered in Basel, Switzerland.

10,789 Employees
Last Reported Date: 03/12/13
Founded in 1897

lonza group ag-unspon adr (LZAGY) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

lonza group ag-unspon adr (LZAGY) Key Developments

Precision Biosciences Files Patent Infringement Lawsuit Against Lonza Group

Precision BioSciences Inc. announced that it has filed a patent infringement lawsuit against Lonza Group and a number of its affiliates in the U.S. District Court for the District of Delaware. The lawsuit seeks a ruling that Lonza's importation into the United States and the use, offer for sale, and sale in the United States of the GS Xceed(TM) Gene Expression System and CHOK1SV knock-out cell line infringe U.S. Patent No. 8,377,674, which applies Precision BioSciences' Directed Nuclease Editor(TM) genome editing technology. The lawsuit requests monetary damages as well as a permanent injunction preventing Lonza from importing the GS Xceed(TM) Gene Expression System and CHOK1SV knock-out cell line into the United States and from using, selling or offering to sell those materials in the United States. Precision controls a rapidly growing patent estate consisting of eighteen issued genome engineering patents. Precision's European and Australian patents claim methods that are similar to those claimed in the '674 patent. Certain of the European and Australian patent claims describe methods for modifying DNA in cells, such as the CHOK1SV cell line, using an engineered meganuclease.

Lonza Group AG Reiterates EBIT Guidance for 2013

Lonza Group AG reiterates its EBIT guidance growth of approximately 10% for 2013.

Lonza Group AG, Q1 2013 Earnings Call, Apr 25, 2013

Lonza Group AG, Q1 2013 Earnings Call, Apr 25, 2013

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LZAGY:US $7.65 USD -0.02

LZAGY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Albemarle Corp $63.99 USD +0.69
Clariant AG SFr.13.89 CHF 0.00
Croda International PLC 2,461 GBp +72.00
Dr Reddy's Laboratories Ltd 2,103 INR -28.45
Rockwood Holdings Inc $67.51 USD +0.33
View Industry Companies
 

Industry Analysis

LZAGY

Industry Average

Valuation LZAGY Industry Range
Price/Earnings 20.1x
Price/Sales 0.9x
Price/Book 1.5x
Price/Cash Flow 20.5x
TEV/Sales 0.1x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LONZA GROUP AG-UNSPON ADR, please visit www.lonza.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.